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Abstract
Introduction
Tolerogenic dendritic cells (DCs) have the potential to prolong graft survival after transplanta-
tion. Tolerogenic DCs are in general characterized by a low expression of co-stimulatory mole-
cule and a high IL-10:IL-12 production ratio. Based on promising results with earlier used
alternatively activated DCs, we aimed to generate in culture potentially tolerogenic DC by simul-
taneously blocking GSK3 by lithium chloride (LiCl) and stimulating TLR2 by PAM3CysSerLys4.
Materials and Methods
Bone marrow-derived LiClPAM3 DCs were generated by the addition of LiCl 24 hours
before harvesting, and one hour later PAM3CysSerLys4. The phenotype of the DCs was
assessed by determining the expression of co-stimulatory molecules in flow cytometry and
cytokine production in ELISA, whereas their functional properties were tested in a mixed
lymphocyte reaction. A fully MHCmismatched heterotopic heart transplant preceded by
infusion of donor-derived LiClPAM3 DC was performed to assess the tolerogenic potential
of LiClPAM3 DCs in vivo.
Results
LiClPAM3 DCs displayed a tolerogenic phenotype accompanied with a low expression of
co-stimulatory molecules and a high IL-10:IL-12 production ratio. However, in mixed lym-
phocyte reaction, LiClPAM3 DCs appeared superior in T cell stimulation, and induced Th1
and Th17 differentiation. Moreover, mice pretreated with LiClPAM3 DC displayed a reduced
graft survival. Analysis of LiClPAM3 DC culture supernatant revealed high levels of CXCL-
1, which was also found in supernatants of co-cultures of LiClPAM3 DC and T cells. Never-
theless, we could not show a role for CXCL-1 in T cell proliferation or activation in vitro.
Discussion
LiClPAM3 DCs display in vitro a tolerogenic phenotype with a high IL-10:IL-12 ratio, but
appeared to be highly immunogenic, since allograft rejection was accelerated. As yet
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unidentified LiClPAM3 DC-derived factors, may explain the immunogenic character of LiCl-
PAM3 DCs in vivo.
Introduction
Dendritic cells (DCs) are professional antigen presenting cells that can induce activation and
differentiation of T cells by a combination of 3 signals: (1) recognition of an antigen-MHC
complex by the T cell receptor, (2) engagement of co-stimulatory molecules and, (3) binding of
cytokines produced by the DC to cytokine receptors on T cells. While several subsets of DCs
are distinguished, including myeloid and plasmacytoid DC, each of these subsets can have
either immunogenic or tolerogenic effects. An immunogenic or tolerogenic outcome is mainly
determined by the maturation state of the DC, which is reflected by the expression level of co-
stimulatory molecules [1]. In numerous animal studies of organ transplantation, prolonged
allograft survival has been achieved after injection of tolerogenic, either immature or semi-
mature, donor-derived or autologous DCs prior to transplantation [2]. Also in experimental
auto-immune diseases, the infusion of tolerogenic DCs has been demonstrated to abate unde-
sirable immune responses [3]. Various strategies and pharmacological agents have been used
in DC cultures in order to create tolerogenic DCs. Unifying characteristics of tolerogenic DCs
are a low expression of co-stimulatory molecules [4–6], and a favorable cytokine profile in gen-
eral characterized by a low secretion rate of IL-12 and an increased secretion rate of IL-10. Tol-
erogenic (human or murine) DCs with an increased IL-10:IL-12 secretion ratio have been
generated after culture with different cytokines as IL-10 and TGFβ1 [7,8], and with different
pharmacological substances such as glucocorticoids [9,10], vitamin D analogues [11,12],
3-hydroxy-3-methylglutaryl-CoA reductase inhibitors [13], curcumin [14]. In addition, incu-
bation of DCs with several toll like receptor (TLR) ligands such as the TLR2 agonists yeast
zymosan [15–17] and Pam3CysSerLys4 [18], the TLR4 agonist lipopolysaccharide [19], and the
TLR5 agonist flagellin [18], has been shown to induce tolerogenic DCs in certain conditions.
In a previous study we observed prolonged allograft survival in a heart transplant model in
mice by injecting alternatively activated donor-derived DCs (aaDC, DCs activated with LPS in
the presence of dexamethasone) seven days prior to transplantation [20]. Indeed, these aaDC
were characterized by a low expression of the co-stimulatory molecules CD40 and CD86, and
an increased IL-10:IL-12 secretion ratio. IL-10 is an anti-inflammatory cytokine, especially pro-
duced by DCs upon TLR2 triggering and regulatory T and B cells. The production of IL-10
after TLR2 ligation results from the activation of phosphatidylinositol 3-OH kinase (PI3K) and
subsequent inhibition of glycogen synthase kinase 3 (GSK3). Pharmacologic inhibition of
GSK3 together in combination with TLR2 triggering results in enhanced IL-10 production and
abrogated IL-12 production [21]. The cytokine profile and consequently the tolerogenic poten-
tial of DCs can thus be manipulated by specific TLR triggering and simultaneously targeting
intracellular signal transduction pathways. These findings led us to hypothesize that bone mar-
row-derived mouse DCs, cultured in the presence of a TLR2-agonist (PAM3CysSerLys4) and a
GSK3 inhibitor (lithium chloride, LiCl), could have strong tolerogenic properties rendering
them suitable for extensive prolongation of graft survival in a transplant model. We were
indeed able to culture DCs with a highly tolerogenic phenotype, characterized by a low expres-
sion of co-stimulatory molecules and a high IL-10:IL-12 production ratio. Despite these favor-
able characteristics, however, the LiClPAM3 DCs turned out to superiorly stimulate T cell
proliferation in mixed lymphocyte reaction and to cause accelerated graft rejection in a (heart)
transplant model.
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Materials and Methods
Mice
Experiments were performed with completely MHC-mismatched combinations of male
C57Bl/6N (donor, H-2d) and male Balb/c (graft recipient, H-2b) mice. All mice were obtained
from Charles River Laboratories (USA), aged 6 to 8 weeks old. All animal experiments were
carried out after permission granted by the animal ethics committee of the Radboud University
Nijmegen (Permit Number 2011–024). Animals were housed under specified pathogen-free
conditions and handled according to the guidelines of the local animal welfare body of the Rad-
boud University Nijmegen.
Cell culture
Dendritic cell culture. Donor dendritic cells were cultured from bone marrow derived
cells according to a protocol adapted from Lutz et al. [22,23]. Briefly, C57Bl/6N mice were
euthanized by cervical dislocation, femora and tibia were harvested and bone marrow was
flushed with medium consisting of RPMI-1640 Dutch modification (Invitrogen, Carlsbad,
USA) supplemented with 50 μM β-mercaptoethanol (Sigma-Aldrich, St Louise, USA), 1% glu-
tamax, 1% pyruvate and 10.000 U/ml penicillin-streptomycin (all Invitrogen).
Cells were suspended and subsequently cultured in six well plates (0.8 x 106 cells/well; Corn-
ing Incorporated, USA) containing medium supplemented with 10% fetal calf serum (FCS,
BioWhittaker, Lonza, Walkersville, USA) and 20 ng/ml rGM-CSF (PeproTech, Rocky Hill,
USA). Cells were incubated at 37°C and 5% CO2 for 9 days. To obtain LiClPAM3 DCs, 10 mM
LiCl (L-7026, Sigma-Aldrich Chemie, Steinheim, Germany) was added on the 8th day of culture
and one hour later 1 μg/ml PAM3CysSerLys4 (PAM3, tlrl-pms, InvivoGen, San Diego, USA)
was added. Mature DCs were generated by adding 1 μg/ml ultra pure lipopolysaccharide (ultra
pure LPS from E. coli 0111:B4, Invivogen, San Diego, USA) to untreated cells 24 hours before
harvesting. After 9 days of culture, DC were harvested. Culture supernatant was stored at
-20°C for cytokine measurement later on, cells were used for flow cytometric analysis, mixed
lymphocyte reaction or for intravenous administration to Balb/c mice prior to transplantation.
Mixed lymphocyte reaction. In mixed lymphocyte reactions (MLR), a protocol adapted
from earlier performed MLR [24] was used and 2x105 responder cells (Balb/c) were co-cultured
with 5x104 stimulator cells (C57Bl/6N). To prepare responder cells the spleen was pushed
through a sterile stainless wire mesh (70 μmeter) and erythrocytes were lysed by Ammonium-
Chloride-Potassium lysing buffer. Afterwards, a negative selection was performed with anti-
MHC class II microbeads and a LS column (Miltenyi Biotec GmbH, Gladbach, Germany).
Before selection, the splenocytes contained 38% T cells and 50% B cells. After selection, the
negative fraction consisted of 82% T cells and 5% B cells. Splenocytes or enriched T cells were
intracellular labeled with CFSE (Molecular Probes, Life Technologies Ltd, Paisley, UK) accord-
ing to the manufacturer’s instructions. Stimulator cells consisted of dendritic cells, cultured as
described above and washed three times before co-culture with the responder cells. Responder
and stimulator cells were co-cultured in medium supplemented with 10% FCS as described
above in a 96-wells round bottom plate (Costar, Corning Inc. USA). Where indicated, αCXCL-
1 (Clone 48415, R&D Systems) or isotype control (Rat IgG2A, R&D Systems), or a selective
CXCR2-antagonist, SB225002 (Cayman Chemical, Michigan USA) or vehicle (sterile DMSO,
Sigma Aldrich) was added to the MLR.
Cells were incubated at 37°C, 95% humidity and 5% CO2. At day 4 and 6 of culture, cells
were harvested. Culture supernatant was collected and stored at -20°C for cytokine analysis.
Proliferation of responder cells was measured by dilution of CFSE signal by flow cytometry.
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Heart transplantation
Seven days prior to heart transplantation, graft recipients (Balb/c mice) were intravenously
(tail vein) infused with 106 C57Bl/6N DCs of one of the three different types (control, LPS or
LiClPAM3). Before surgery, C57Bl/6N donor mice were anesthetized by subcutaneous injec-
tion of FFM-mix (fentanyl citrate, fluanisone, midazolam, 0.2ml per 10 grams of body weight).
Recipient mice (Balb/c) were anesthetized by isoflurane inhalation and subcutaneous injection
of FFM-mix (0.1 ml per 10 grams of body weight). The heart graft was placed in a heterotopic
position (intra-abdominal) according to the technique described by Corry et al. [25]. After sur-
gery, intramuscular injection of buprenorfine was used as analgesic medication. Graft survival
was monitored by daily transabdominal palpation of the donor heart. In case of strong decrease
in strength of heart pulsation or absent pulsation, rejection was scored. Mice were daily moni-
tored for transplant function, weight and well being (scored for general appearance and behav-
ior, appearance of fur and mucous membranes, respiration rate and signs of dehydration).
After a follow up of 18 days, mice were euthanized by cervical dislocation. Ten percent of the
included mice did not reach the experimental endpoint because they died suddenly or were
euthanized after reaching a human endpoint.
Antibodies
In flow cytometry (BD FACS Calibur, New Jersey, USA) the following monoclonal antibodies
were used for cell staining: CD3 (clone 17A2, rat monoclonal, diluted 1:100, BD Biosciences,
New Jersey, USA), CD11c (clone N418, hamster monoclonal, diluted 1:100, ABD Serotec,
Kidlington, UK), CD19 (clone 1D3, rat monoclonal, diluted 1:100, BD Biosciences), CD40
(clone FGK45.5, rat monoclonal, diluted 1:40, Miltenyi), CD86 (clone PO3.1, rat monoclonal,
diluted 1:80, eBioscience), CD80 (clone 16-10A1, rat monoclonal, diluted 1:400, Biolegend,
Fell, Germany), MHCII (clone M5/114.15.2, rat monoclonal, diluted 1:800, eBioscience). All
used antibodies have been validated by others [22]. The cytokines IL-1β, IL-4, IL-6, IL-10, IL-
12, IL-17, IL-21, IL-23, TNF-α, IFN-γ (all eBioscience) and CXCL-1 (R&D systems, Minneapo-
lis, USA) were measured in supernatants of bone marrow derived DC culture and MLR culture
by using ELISA kits according to the manufacturer’s instructions.
A protein-based mouse cytokine/chemokine antibody array (Ray Biotech Inc, Norcross,
USA) was performed on DC culture supernatant for comparative analysis of levels of a broad
panel of 120 chemokine, cytokine and growthfactors in pooled supernatants of different types
of DC cultures.
Statistical analysis
For statistical analysis GraphPad Prism (version 5.0 for Windows, GraphPad Software, San
Diego, USA) was used. Results are expressed as mean ± SD. For comparison between two
groups the Mann-Whitney U test was used. Graft survival was compared using Kaplan-Meier
curves and the log rank test. A P-value< 0.05 was considered significant.
Results
Combined TLR2 triggering and GSK3 inhibition generates DCs with
features of a tolerogenic phenotype
Immature bone marrow derived DC were treated with LiCl to inhibit GSK3 and subsequently
stimulated with the TLR2 ligand PAM3CysSerLys4 (LiClPAM3 DC). Like untreated immature
DCs, a low percentage of the LiClPAM3 DCs was positive for the co-stimulatory molecules
CD40 and CD86 (Fig 1A and 1B). After stimulation with LPS, an expected strong increase in
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the percentage of CD40+ and CD86+ cells was observed. The expression of CD80 and MHCII
was comparable between LiClPAM3 DCs and untreated immature DCs.
The cytokine secretion by the various types of DCs was measured in the supernatants
obtained at day 9 of DC culture (Fig 1C). As compared to immature control DC, LiClPAM3
DCs produced much higher levels of IL-10, while levels of IL-12 were equally low, resulting in
a high IL-10:IL-12 ratio (Fig 1D) fitting with a tolerogenic potential. An opposite profile with
high IL-12 levels and low IL-10 levels was observed after stimulation with LPS. While IL-1β lev-
els in LiClPAM3 DC culture supernatant exceeded that of LPS DC, levels of IL-6 and IL-23
were significantly lower. TNF-α levels were comparable in the supernatants of LPS and LiCl-
PAM3 DCs, while levels of IL-4, IL-21 and interferon-γ were undetectable. Although DCs
treated with LiCl or PAM3 alone also displayed a low expression of CD40 and CD86, their IL-
10:IL-12 ratio was lower than that of the LiClPAM3 DC (S1 Fig).
Taken together, the cultured LiClPAM3 DCs display characteristic features of a tolerogenic
phenotype with a low expression of co-stimulatory molecules and a high IL-10:IL-12 ratio.
LiClPAM3 DCs are potent T cell stimulators and induce TH1 and TH17
differentiation
In an allogeneic mixed lymphocyte reaction, the stimulatory capacity of the LiClPAM3 DC was
analyzed. MHCII-depleted, CFSE stained Balb/c splenocytes were co-cultured with C57Bl/6N
DCs for 3–6 days.
As expected, stimulation with immature DCs resulted in low proliferative T cell responses
(Fig 2A). Surprisingly, in cultures with LiClPAM3 DCs we observed high proliferative T cell
responses, which were similar to that after stimulation with LPS DCs (Fig 2B). Upon LiCl-
PAM3 DC stimulation, T cells produced mainly IFN-γ (Fig 2C) and IL-17 (Fig 2D), suggesting
a shift towards Th1 and Th17 differentiation. Comparable levels of IFN-γ and IL-17 were
found in supernatants of co-cultures containing LPS DCs, whereas levels of IL-10, IL-21 and
TNF-α were undetectable.
Thus, in vitro, LiClPAM3 DCs display an immunogenic character, demonstrated by strong
T cell stimulatory capacity and interferon-γ and IL-17 production in co-culture.
Pretreatment of recipients with LiClPAM3 DCs results in accelerated
heart graft rejection
To test the effects of the phenotypic tolerogenic LiClPAM3 DCs in vivo, we pretreated mice
with donor-derived DCs and performed a fully MHC-mismatched heterotopic vascularized
heart transplantation. Pretreatment of recipients with LiClPAM3 DCs resulted in a median
graft survival of 3 days (n = 9), which was comparable to graft survival after pretreatment with
mature LPS DCs (median graft survival of 4 days, n = 9), though significantly shorter than
after pretreatment with immature control DC (median graft survival of 10 days (n = 10; Fig 3).
Syngeneic transplanted mice, pretreated with LiClPAM3 DCs (n = 4), survived until the end of
follow up.
Fig 1. LiClPAM3 dendritic cells (DCs) display characteristic features of a tolerogenic phenotype with high IL-10:IL-
12 ratio. Bonemarrow-derived C57Bl/6N DCs were cultured for 9 days with GM-CSF. Cells were gated for CD11c+ (A) and
subsequently analyzed by flow cytometry for percentage of CD40, CD80, CD86, and MHCII cells (black lines, grey area
depicts unstained cells). The percentage of CD40+ or CD86+ cells was lower in LiClPAM3 DC compared to LPS DC
(* p<0.05) (B). Supernatants obtained after 9 days of DC culture were analyzed for cytokines (** p<0.01) (C). LiClPAM3
DCs have a higher IL-10:IL-12 ratio compared to LPS and control DC (** p<0.01) (D). Results are of 6 independent
experiments.
doi:10.1371/journal.pone.0159986.g001
Allostimulatory Effects of Dendritic Cells with Characteristic Features of a Regulatory Phenotype
PLOS ONE | DOI:10.1371/journal.pone.0159986 August 15, 2016 6 / 15
Allostimulatory Effects of Dendritic Cells with Characteristic Features of a Regulatory Phenotype
PLOS ONE | DOI:10.1371/journal.pone.0159986 August 15, 2016 7 / 15
In conclusion, the LiClPAM3 DCs appeared to be strongly immunogenic in vivo with accel-
erated graft rejection.
LiClPAM3 DCs produce high amounts of the chemokine CXCL-1
While several features of the LiClPAM3 DCs suggested a tolerogenic potential, in vitro and in
vivo experiments revealed robust allostimulatory capacity. To unravel this unexpected discrep-
ancy, further analysis of cytokine, chemokine and growth factor production by LiClPAM3 DCs
was performed using a protein-based cytokine/chemokine array, followed by ELISA of cyto-
kines and chemokines of interest. The cytokine/chemokine array indicated relatively high levels
of CXCL-1, IL-12, CCL-11, CXCL-5, CXCL-11 and soluble TNF-α receptor type 1 (sTNF-α
RI) in the culture supernatant of LiClPAM3 DCs (S1 Table). Based on literature data on the
role of these proteins in DC-T cell interaction and Th1/TH17 differentiation [26–28], we
focused on CXCL-1 and confirmed with ELISA high levels of CXCL-1 in LiClPAM3 DC culture
supernatant, significantly higher than in supernatants of LPS or control DC (Fig 4A). We next-
analyzed MLR supernatants and again found high levels of CXCL-1 in LiClPAM3 DC stimu-
lated culture supernatants, whereas CXCL-1 levels appeared undetectable in culture superna-
tants of LPS DC and control DC stimulated conditions (Fig 4B).
Fig 2. LiClPAM3 dendritic cells (DCs) are potent T cell stimulators and induce Th1 and Th17 differentiation in vitro.
The T cell stimulatory capacity of (C57Bl/6N) LiClPAM3 DCs was tested in mixed lymphocyte reaction. (Balb/c) T cell
proliferation was analyzed by dilution of CFSE signal (A). LiClPAM3 DC stimulation resulted in higher T cell proliferation at
days 3, 4, 5, and 6 compared to control DC stimulation (*p<0.05) (B). T cell differentiation was analyzed by measuring
cytokine in co-culture supernatants in ELISA. Interferon-γ (C), but not IL-17 (D) production, by LiClPAM3 DC stimulated T
cells was higher compared to LPS DC stimulated T cells at day 4 (* p<0.05). IL-4, IL-6 and IL-23 levels did not differ between
groups (E). Results are of 3 independent experiments.
doi:10.1371/journal.pone.0159986.g002
Fig 3. LiClPAM3 DC pre-treatment results in accelerated allograft rejection in a fully MHCmismatched heterotopic heart transplant
model. Balb/c recipient mice were intravenously infused with 106 C57Bl/6N donor-derived DC or syngeneic DC seven days prior to
transplantation. Graft survival was daily assessed by transabdominal palpation of the donor heart. LiClPAM3 DC pre-treatment (n = 9) resulted in
accelerated allograft rejection compared to control DC pretreated mice (n = 10) (**p<0.01).
doi:10.1371/journal.pone.0159986.g003
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Fig 4. LiClPAM3 DC produce high levels of CXCL-1 in culture, which sustains in co-culture with MHCII-
depleted splenocytes. CXCL-1 was measured in (C57Bl/6N) DC culture supernatant after 9 days of culture (A).
LiClPAM3 DC produce large amounts of CXCL-1 during culture, significantly higher as compared to LPS DC
(**p<0.01). In supernatant of LiClPAM3 DC stimulated (Balb/c) T cells (B) higher levels of CXCL-1 were found as
compared to LPS DC stimulated conditions (** p<0.01). Results are of 5 independent experiments.
doi:10.1371/journal.pone.0159986.g004
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LiClPAM3 DC-derived CXCL-1 is not responsible for the proliferative T
cell response
Based on the immunogenic character of the LiClPAM3 DC combined with high production of
CXCL-1, we postulated that LiClPAM3 DC-derived CXCL-1 could induce T cell proliferation.
To test our hypothesis, we performed MLRs in which we neutralized LiClPAM3 DC-derived
CXCL-1 with anti-CXCL-1 or blocked CXCR2, the receptor of CXCL-1.
First, we neutralized DC derived CXCL-1 by adding anti-CXCL-1 (or isotype control) to co-
cultures of LiClPAM3 DC and MHCII-depleted splenocytes. Neutralization of DC derived
CXCL-1 did not influence T cell proliferation (Fig 5A) or activation (Fig 5B). In addition, selec-
tive blockade of CXCR2 by the chemical substance SB225002 could not abolish the prolifer-
ative response (Fig 5C) or activation (Fig 5D) of T cells either.
In conclusion, although the immunogenic LiClPAM3 DC were characterized by the produc-
tion of high levels of CXCL-1, we were not able to show that LiClPAM3 DC-derived CXCL-1 is
directly responsible for the increased T cell activation and proliferation.
Discussion
Cellular vaccination with tolerogenic DCs prior to transplantation to create donor-specific tol-
erance is a promising approach in transplantation medicine [2]. Characteristic features of these
Fig 5. LiClPAM3 DC derived CXCL-1 is not involved in T cell activation or proliferation. Balb/c MHCII-depleted splenocytes were co-cultured
for 4–6 days with C57Bl/6N LiClPAM3 DC in the presence of a CXCL-1 neutralizing antibody, or an isotype control. Neutralization of DC derived
CXCL-1 did not affect T cell proliferation (A) or activation (B) (n = 5). Selective chemical CXCR2 blockade by SB225002 did not result in reduced T
cell proliferation (C) or activation (D) caused by CXCR2 blockade, compared to vehicle only (n = 3).
doi:10.1371/journal.pone.0159986.g005
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tolerogenic DCs are a high IL-10:IL-12 secretion ratio and low expression of co-stimulatory
molecules, which drives T cell differentiation towards regulatory T cells and T cell anergy.
Previously, we generated alternatively activated DCs by adding dexamethasone and LPS,
which resulted in DC with a low CD40, CD86 and MHCII expression and an increased IL-10:
IL-12 ratio compared to both immature and LPS-matured DCs [20]. In tolerogenic DCs
described in literature a decreased secretion of other pro-inflammatory cytokines, such as
TNF-α, IL-6, and an increased secretion of other anti-inflammatory cytokines, such as TGF-β,
has been reported as well. Nevertheless, the majority of studies mention a low expression of co-
stimulatory molecules and a high IL-10:IL-12 ratio.
Based on the finding that combined TLR2 triggering and GSK3 inhibition results in a high
IL-10:IL-12 production ratio [21], we manipulated bone marrow-derived dendritic cells in cul-
ture by adding LiCl (inhibitor of GSK3) and PAM3CysSerLys4 (TLR2 agonist). Indeed, a low per-
centage of the generated LiClPAM3 DCs expressed co-stimulatory molecules and the cells
displayed a high IL-10:IL-12 secretion ratio. Despite these characteristic features of a tolerogenic
phenotype, LiClPAM3 DCs appeared to have a highly immunogenic character in vitro. When
these DCs were used in co-cultures with responder lymphocytes, high levels of IL-17 and inter-
feron-γ were found. Based on the proliferative response of the lymphocytes, we interpret this as
a skewing towards Th1 and Th17 subsets, although both IL-17 and interferon-γ producing
(Foxp3+) regulatory T cell populations have been demonstrated in humans [26–28]. Since IL-12
production by LiClPAM3 DC is low, we suggest that the increased production of IL-1βmay have
contributed to this Th17 shift, since this cytokine has the potential to direct naive T cells towards
Th17 [29,30]. The in vitro immunogenic character of the LiClPAM3 DC was confirmed in vivo
by accelerated graft rejection after LiClPAM3 DC infusion prior to heart transplantation. Since
we found high levels of the chemokine CXCL-1 in both LiClPAM3 DC cultures and supernatants
of MLRs where these DCs were used as stimulators, we speculated that CXCL-1 was responsible
for the increased T cell response and accelerated allograft rejection. CXCL-1, also called KC or
GRO-α, is mainly known as an important regulator of neutrophil recruitment [31] and activation
[32]. The sole receptor for CXCL-1 is CXCR2, which is reported to be expressed by mouse T cells
[33,34]. However, further analysis could not substantiate a direct role for CXCL-1 in T cell activa-
tion or proliferation. Likely, another LiClPAM3 DC derived factor, soluble or cell bound, is
responsible for the unexpected immunogenic character of the LiClPAM3 DC.
Glycogen synthase kinase 3 is a ubiquitous serine/threosine kinase involved in multiple cel-
lular functions, as cell signaling [35], cell division [36] and cell proliferation [37]. By regulation
of the transcription factors nuclear factor κB (NFκB) [38], cAMP response element-binding
protein (CREB), and activator protein-1 (AP-1) [39], the isoform GSK3β directly influences
expression of pro- and anti-inflammatory cytokines [21]. Therefore, GSK3β regulates both
innate and adaptive immunity [40]. Focusing on DC and T cell functioning, GSK3 inhibition
has recently been associated with increased IL-10 production in different T helper cell subsets
[41] and reduced TNF-α production by human lymphocytes [42]. GSK3 inhibition in dendritic
cells has been associated with both interferon-β and LPS induced IL-10 production [43,44],
while IL-12p40 production was decreased in GSK3β1 silenced (but not LiCl treated) and TLR2
triggered (bovine) endothelial cells [45]. Beneficial anti-inflammatory effects of GSK3 inhibi-
tion have been observed in several animal models, like LPS and Klebsiella pneumonia- induced
sepsis [21,46], LPS-induced acute renal failure [47], and traumatic tissue injury [48,49]. Based
on these data, TLR2 triggering combined with GSK3 inhibition has in theory the potential to
induce tolerogenic DC. While the phenotype of the cultured LiClPAM3 DCs we generated sup-
ported this hypothesis, this was not confirmed by the functional characteristics of these cells,
which stresses the importance of performing adequate functional (in vivo) tests when evaluat-
ing the immunomodulatory potential of various cell types.
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Collectively, although TLR2 triggering and GSK3 inhibition increased the IL-10:IL-12 secre-
tion ratio, this did not result in a desired tolerogenic capacity of LiClPAM3 DCs. Our results
indicate that the LiClPAM3 DCs have a direct influence on T cell function and differentiation,
though not mediated by CXCL-1. In an attempt to generate donor-specific tolerance we
focused on the co-stimulatory molecule expression and cytokine profile of DC, since these fac-
tors are known to direct T cell differentiation during DC–T cell interaction [50]. Although DC
derived IL-10 is capable in skewing a naïve T cell towards a regulatory phenotype [51], other
cytokines may override the tolerogenic effect of IL-10. LiClPAM3 DCs produce besides IL-10
also pro-inflammatory cytokines as IL-1β, IL-6, TNF-α and IL-12. It is therefore most likely
that the composition of the resulting cytokine and chemokine cocktail has determined the
immunogenic character of the LiClPAM3 DCs in MLR in vitro and experimental transplanta-
tion in vivo.
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